Susquehanna International Group
CLVS

Susquehanna International Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Susquehanna International Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-503,000
Closed -$599K – 14379
2022
Q3 		$599K Sell
503,000
-310,000
-38% -$483K ﹤0.01% 7997
2022
Q2 		$1.46M Buy
813,000
+276,100
+51% +$407K ﹤0.01% 5594
2022
Q1 		$1.08M Sell
536,900
-173,300
-24% -$340K ﹤0.01% 6906
2021
Q4 		$1.93M Buy
710,200
+112,000
+19% +$414K ﹤0.01% 5599
2021
Q3 		$2.67M Sell
598,200
-341,000
-36% -$1.64M ﹤0.01% 5210
2021
Q2 		$5.45M Sell
939,200
-342,900
-27% -$2.01M ﹤0.01% 3889
2021
Q1 		$9M Buy
1,282,100
+27,900
+2% +$187K ﹤0.01% 2955
2020
Q4 		$6.02M Buy
1,254,200
+412,300
+49% +$2.09M ﹤0.01% 3144
2020
Q3 		$4.91M Sell
841,900
-79,300
-9% -$474K ﹤0.01% 3074
2020
Q2 		$6.22M Buy
921,200
+83,200
+10% +$630K ﹤0.01% 2710
2020
Q1 		$5.33M Sell
838,000
-822,500
-50% -$6.6M ﹤0.01% 2498
2019
Q4 		$17.3M Buy
1,660,500
+1,191,900
+254% +$8.67M 0.01% 1557
2019
Q3 		$1.84M Buy
468,600
+243,000
+108% +$1.97M ﹤0.01% 4381
2019
Q2 		$3.35M Sell
225,600
-641,800
-74% -$11.6M ﹤0.01% 3276
2019
Q1 		$21.5M Buy
867,400
+23,200
+3% +$582K 0.01% 1144
2018
Q4 		$15.2M Buy
844,200
+392,200
+87% +$8.01M 0.01% 1265
2018
Q3 		$13.3M Buy
452,000
+36,700
+9% +$1.42M ﹤0.01% 1678
2018
Q2 		$18.9M Sell
415,300
-6,400
-2% -$311K 0.01% 1345
2018
Q1 		$22.3M Sell
421,700
-16,700
-4% -$974K 0.01% 1142
2017
Q4 		$29.8M Buy
438,400
+68,900
+19% +$4.82M 0.01% 986
2017
Q3 		$30.4M Sell
369,500
-90,300
-20% -$7.16M 0.01% 939
2017
Q2 		$43.1M Buy
459,800
+168,100
+58% +$10.3M 0.02% 688
2017
Q1 		$18.6M Sell
291,700
-183,600
-39% -$11.2M 0.01% 1130
2016
Q4 		$21.1M Sell
475,300
-65,700
-12% -$2.31M 0.01% 1002
2016
Q3 		$19.5M Buy
541,000
+263,500
+95% +$5.65M 0.01% 1033
2016
Q2 		$3.81M Sell
277,500
-64,700
-19% -$946K ﹤0.01% 2587
2016
Q1 		$6.57M Buy
342,200
+66,000
+24% +$1.4M ﹤0.01% 1967
2015
Q4 		$9.67M Buy
276,200
+65,900
+31% +$4.25M ﹤0.01% 1790
2015
Q3 		$19.3M Sell
210,300
-83,600
-28% -$7.23M 0.01% 1234
2015
Q2 		$25.8M Buy
293,900
+168,100
+134% +$14.4M 0.01% 1091
2015
Q1 		$9.34M Sell
125,800
-1,200
-0.9% -$84.7K ﹤0.01% 1952
2014
Q4 		$7.11M Buy
127,000
+24,600
+24% +$1.29M ﹤0.01% 2404
2014
Q3 		$4.64M Sell
102,400
-106,100
-51% -$4.43M ﹤0.01% 3132
2014
Q2 		$8.63M Buy
208,500
+84,800
+69% +$4.37M ﹤0.01% 2283
2014
Q1 		$8.57M Buy
123,700
+46,000
+59% +$3.38M ﹤0.01% 2196
2013
Q4 		$4.68M Sell
77,700
-26,400
-25% -$1.44M ﹤0.01% 3038
2013
Q3 		$6.33M Buy
+104,100
New +$7.38M ﹤0.01% 2413

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Susquehanna International Group's CLVS Position: Q4 2022 in Review

Susquehanna International Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 505,343 shares — an estimated $601K sold.

Susquehanna International Group first reported a position in CLVS in Q2 2013 and held it in 37 quarters. The position peaked at $24.9M in Q4 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Susquehanna International Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Susquehanna International Group sold 505,343 Clovis Oncology, Inc. shares in Q4 2022, an estimated $601K.
  • Susquehanna International Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 37 quarters.
  • Susquehanna International Group's Clovis Oncology, Inc. position peaked at $24.9M in Q4 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.